Hematologic Malignancy Center

The Hematologic Malignancy Center offers specialized programs for the treatment of leukemia, lymphoma, histiocytosis, and lymphadenopathy through Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children's Hospital. Our center played a key role in refining treatment for childhood leukemia, resulting in today's cure rates of more than 90 percent for pediatric acute lymphoblastic leukemia, and we continue to lead high-impact clinical trials designed to increase cure rates and decrease treatment-related toxicities for long-term survivors.

Conditions We Treat

Leukemia

• Acute lymphoblastic leukemia (ALL), including relapsed acute lymphoblastic leukemia
• Acute myeloid leukemia (AML)
• Chronic myeloid leukemia (CML)
• Juvenile myelomonocytic leukemia

Lymphoma

• Hodgkin lymphoma
• Non-Hodgkin lymphomas
  • Anaplastic large cell lymphoma
  • Burkitt lymphoma
  • Diffuse large B-cell lymphoma
  • Lymphoblastic lymphoma
  • Primary mediastinal B-cell lymphoma
  • Rare non-Hodgkin lymphomas

Histiocytosis

• Langerhans cell histiocytosis (LCH)
• Hemophagocytic lymphohistiocytosis (HLH)

Specialized Treatment Programs for Hematologic Malignancies

• Histiocytosis Program
• Leukemia Program
• Lymphoma Program
• Node Assessment Program

Please visit the Dana-Farber Cancer Institute website to learn more about our Hematologic Malignancy Center, including information about:

• Our pediatric hematologists/oncologists
• Conditions we treat
• Specialized treatment programs
• Hematologic malignancy clinical trials